Form 4: Provectus Biopharmaceuticals CEO Acquires $85,000 Convertible Note in Company's 2025 Financing

Edward Pershing, CEO and Director of Provectus Biopharmaceuticals, Inc., has acquired an $85,000 convertible promissory note as part of the company's 2025 financing efforts.

Summary

• Edward Pershing, the Chief Executive Officer and a Director of Provectus Biopharmaceuticals, Inc. (PVCT), acquired an 8% Unsecured Convertible Promissory Note with a principal amount of $85,000 on May 23, 2025.
• The note is convertible into shares of Series D-1 Convertible Preferred Stock at a price of $2.862 per share.
• The conversion can be elected voluntarily by the reporting person at any time while the note is outstanding.
• The note will automatically convert into Series D-1 Preferred Stock on May 23, 2026, which is twelve months after its issue date.
• Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock.
• The Series D-1 Preferred Stock will automatically convert into Common Stock on June 26, 2026, unless converted earlier.
• The filing also indicates a disposition of 29,700 shares of Series D-1 Convertible Preferred Stock, with the reporting person beneficially owning 1,935,000 shares of Common Stock following the reported transactions.

Sentiment

Score: 7

Explanation: The sentiment is generally positive due to insider buying by the CEO, which signals confidence. However, the complexity of the financial instruments and the slightly ambiguous reporting of the preferred stock disposition temper the score slightly.

Positives

• The acquisition of the convertible note by the CEO demonstrates insider confidence and investment in the company's future.
• The transaction is part of the Issuer's 2025 Financing, indicating successful capital raising efforts by the company.

Negatives

• The complex structure of the convertible note and preferred stock, along with the ambiguous reporting of a 'disposition' of preferred stock without a clear transaction date, could lead to some confusion for investors.

Risks

• Potential dilution for existing common shareholders upon the conversion of the 8% Unsecured Convertible Promissory Note into Series D-1 Preferred Stock and subsequently into Common Stock.
• The value of the investment is subject to the future performance of Provectus Biopharmaceuticals' stock price and its ability to execute its strategic plans.

Future Outlook

The 8% Unsecured Convertible Promissory Note will automatically convert into Series D-1 Preferred Stock on May 23, 2026. Subsequently, the Series D-1 Preferred Stock will automatically convert into Common Stock on June 26, 2026, unless earlier converted.

Management Comments

• The acquisition of the convertible note by CEO Edward Pershing signals his direct financial commitment and belief in the company's strategic direction and future prospects.

Industry Context

This insider transaction reflects a common financing mechanism in the biopharmaceutical industry, where convertible notes are used to raise capital, often from existing stakeholders or institutional investors. The CEO's participation underscores confidence, which can be a positive signal in a sector often reliant on sustained investment for research and development.

Related Party Transactions

• Edward Pershing, as CEO and Director, acquired a convertible promissory note from Provectus Biopharmaceuticals, Inc., constituting a related party transaction.

Stakeholder Impact

• Shareholders: Potential for increased confidence due to insider investment, but also potential for future dilution upon conversion of the note and preferred stock into common shares.
• Creditors: The 8% unsecured convertible promissory note represents a new debt instrument, impacting the company's capital structure.

Next Steps

• Automatic conversion of the 8% Unsecured Convertible Promissory Note into Series D-1 Preferred Stock on May 23, 2026.
• Automatic conversion of Series D-1 Preferred Stock into Common Stock on June 26, 2026.

Key Dates

Keywords

Provectus Biopharmaceuticals, PVCT, Edward Pershing, Convertible Note, Series D-1 Preferred Stock, Common Stock, Insider Transaction, SEC Form 4, Beneficial Ownership, Corporate Finance, Capital Raise, Biotechnology, Pharmaceuticals